首页 > 最新文献

JACC. Heart failure最新文献

英文 中文
Life’s Essential 8 and Incident Heart Failure Among REGARDS Participants With and Without Diabetes 在有和没有糖尿病的参与者中,生命的必要因素和偶发性心力衰竭。
IF 11.8 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-02-01 Epub Date: 2025-10-08 DOI: 10.1016/j.jchf.2025.102686
Yulia Khodneva MD, PhD , Andrea L. Cherrington MD , Pankaj Arora MD , Jessica Blair PhD , Monika M. Safford MD , Ro-Jay Reid MD , Madeline R. Sterling MD , Megan Nordberg MPH , Parag Goyal MD , Emily B. Levitan ScD
{"title":"Life’s Essential 8 and Incident Heart Failure Among REGARDS Participants With and Without Diabetes","authors":"Yulia Khodneva MD, PhD , Andrea L. Cherrington MD , Pankaj Arora MD , Jessica Blair PhD , Monika M. Safford MD , Ro-Jay Reid MD , Madeline R. Sterling MD , Megan Nordberg MPH , Parag Goyal MD , Emily B. Levitan ScD","doi":"10.1016/j.jchf.2025.102686","DOIUrl":"10.1016/j.jchf.2025.102686","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"14 2","pages":"Article 102686"},"PeriodicalIF":11.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thin Evidence, Heavy Need 证据不足,需求巨大:针对HFrEF患者的GLP-1激动剂试验案例。
IF 11.8 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-02-01 Epub Date: 2025-10-23 DOI: 10.1016/j.jchf.2025.102715
Amanda R. Vest MBBS, MPH , Anita Deswal MD, MPH
{"title":"Thin Evidence, Heavy Need","authors":"Amanda R. Vest MBBS, MPH , Anita Deswal MD, MPH","doi":"10.1016/j.jchf.2025.102715","DOIUrl":"10.1016/j.jchf.2025.102715","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"14 2","pages":"Article 102715"},"PeriodicalIF":11.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145339418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of GLP-1 RA Initiation in Patients With HFrEF and Implantable Cardiac Devices Divided for BMI Values GLP-1对HFrEF和植入式心脏装置患者RA起始的影响
IF 11.8 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-02-01 Epub Date: 2026-02-02 DOI: 10.1016/j.jchf.2025.102839
Celestino Sardu MD, MSc, PhD , Ferdinando Carlo Sasso MD , Raffaele Marfella MD, PhD
{"title":"Effects of GLP-1 RA Initiation in Patients With HFrEF and Implantable Cardiac Devices Divided for BMI Values","authors":"Celestino Sardu MD, MSc, PhD , Ferdinando Carlo Sasso MD , Raffaele Marfella MD, PhD","doi":"10.1016/j.jchf.2025.102839","DOIUrl":"10.1016/j.jchf.2025.102839","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"14 2","pages":"Article 102839"},"PeriodicalIF":11.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146098444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond the IVC 超越IVC
IF 11.8 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-02-01 Epub Date: 2026-02-02 DOI: 10.1016/j.jchf.2025.102832
Abhilash Koratala MD , Amir Kazory MD
{"title":"Beyond the IVC","authors":"Abhilash Koratala MD , Amir Kazory MD","doi":"10.1016/j.jchf.2025.102832","DOIUrl":"10.1016/j.jchf.2025.102832","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"14 2","pages":"Article 102832"},"PeriodicalIF":11.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146098439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CMR-First in Newly Diagnosed HFrEF cmr首先用于新诊断的HFrEF
IF 11.8 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-02-01 Epub Date: 2026-02-02 DOI: 10.1016/j.jchf.2025.102827
Louis-Marie Desroche MD , Arthur Darmon MD , Charles Burdet MD, PhD , Guillaume Jondeau MD, PhD
{"title":"CMR-First in Newly Diagnosed HFrEF","authors":"Louis-Marie Desroche MD , Arthur Darmon MD , Charles Burdet MD, PhD , Guillaume Jondeau MD, PhD","doi":"10.1016/j.jchf.2025.102827","DOIUrl":"10.1016/j.jchf.2025.102827","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"14 2","pages":"Article 102827"},"PeriodicalIF":11.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146098685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating the Intersection of HFmrEF/HFpEF and CKD: High-Risk With Gaps in Evidence. 导航HFmrEF/HFpEF和CKD的交叉点:高风险与证据差距。
IF 13 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-29 DOI: 10.1016/j.jchf.2026.102941
Wendy McCallum
{"title":"Navigating the Intersection of HFmrEF/HFpEF and CKD: High-Risk With Gaps in Evidence.","authors":"Wendy McCallum","doi":"10.1016/j.jchf.2026.102941","DOIUrl":"https://doi.org/10.1016/j.jchf.2026.102941","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"110 6 1","pages":"102941"},"PeriodicalIF":13.0,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146073213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unique Proteomic Signatures in Human Anthracycline-Induced Dilated Cardiomyopathy. 人类蒽环类药物诱导扩张型心肌病的独特蛋白质组学特征。
IF 13 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-29 DOI: 10.1016/j.jchf.2026.102940
Sharna Jenna Katzeff,Giovanni Guglielmi,Cassandra Malecki,Jovana Babic,Benjamin Hunter,Lakshay Seth,Judy Mullan,Sean Lal
{"title":"Unique Proteomic Signatures in Human Anthracycline-Induced Dilated Cardiomyopathy.","authors":"Sharna Jenna Katzeff,Giovanni Guglielmi,Cassandra Malecki,Jovana Babic,Benjamin Hunter,Lakshay Seth,Judy Mullan,Sean Lal","doi":"10.1016/j.jchf.2026.102940","DOIUrl":"https://doi.org/10.1016/j.jchf.2026.102940","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"3 1","pages":"102940"},"PeriodicalIF":13.0,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146073046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Standardized Reporting in Heart Failure Noninvasive Remote Monitoring Trials: Interventions to Catalyze Data Into Action. 心力衰竭无创远程监测试验的标准化报告:将数据转化为行动的干预措施。
IF 13 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-22 DOI: 10.1016/j.jchf.2025.102849
Elise L Shalowitz,Pardeep Jhund,Mitchell A Psotka,Abhinav Sharma,Matthew Dimond,Trejeeve Martyn,Martin Cowie,Yasbanoo Moayedi,Nathaniel M Hawkins,Justin Ezekowitz,Offer Amir,Maurizio Volterrani,Mona Fiuzat,Christopher O'Connor,David P Kao,
BACKGROUNDNoninvasive remote patient monitoring (RPM) captures and transmits physiological (eg, weight) and symptom data to the patient's care team for monitoring outside of the clinic, creating opportunities for early intervention (eg, medical therapy optimization) to avoid decompensation events. Mixed results in studies of noninvasive RPM may stem from the complex design of heart failure programs. In current RPM study reports, many workflow components including data review and clinical responses are reported ambiguously or not at all. Opaque workflows prevent robust evaluation, replication in other studies, and community implementation of heart failure RPM programs.OBJECTIVESThe purpose of this study was to create a set of recommendations and a template for reporting workflow design in the publication of noninvasive RPM studies.METHODSThe Heart Failure Collaboratory, Canadian Heart Failure Society, and members of the European Society of Cardiology formed a multidisciplinary working group. Through an extensive consensus-building process, the authors reviewed existing workflows and data reporting practices and developed "the 6 Rs" of RPM Reporting.RESULTSThe authors created a set of recommendations and a template for reporting workflows that is organized around 6 Rs: patient Representativeness, ambulatory data Recording, data Relay to clinicians, clinician data Review, Response, and Recommendations from patients and providers.CONCLUSIONSSystematic use of the 6 Rs of RPM Reporting template will improve the completeness and transparency of workflow reporting of RPM studies. The authors encourage investigators to use this framework and accompanying template during noninvasive RPM trial planning and include completed templates in study publications or as supplemental materials.
无创远程患者监测(RPM)捕获并传输生理(如体重)和症状数据给患者的护理团队,以便在诊所外进行监测,为早期干预(如药物治疗优化)创造机会,以避免失代偿事件。无创RPM研究的混合结果可能源于心力衰竭方案的复杂设计。在当前的RPM研究报告中,包括数据审查和临床反应在内的许多工作流程组件的报告含糊不清或根本没有。不透明的工作流程妨碍了其他研究的可靠评估、复制和心力衰竭RPM程序的社区实施。目的本研究的目的是为发表无创RPM研究的报告工作流程设计创建一套建议和模板。方法心力衰竭合作实验室、加拿大心力衰竭学会和欧洲心脏病学会成员组成了一个多学科工作组。通过广泛的共识建立过程,作者回顾了现有的工作流程和数据报告实践,并制定了RPM报告的“6r”。结果:作者创建了一套建议和报告工作流程模板,围绕6个Rs组织:患者代表性、门诊数据记录、数据传递给临床医生、临床医生数据审查、响应以及患者和提供者的建议。结论系统使用6 Rs RPM报告模板将提高RPM研究工作流程报告的完整性和透明度。作者鼓励研究者在无创RPM试验计划中使用该框架和随附模板,并将完成的模板包括在研究出版物中或作为补充材料。
{"title":"Standardized Reporting in Heart Failure Noninvasive Remote Monitoring Trials: Interventions to Catalyze Data Into Action.","authors":"Elise L Shalowitz,Pardeep Jhund,Mitchell A Psotka,Abhinav Sharma,Matthew Dimond,Trejeeve Martyn,Martin Cowie,Yasbanoo Moayedi,Nathaniel M Hawkins,Justin Ezekowitz,Offer Amir,Maurizio Volterrani,Mona Fiuzat,Christopher O'Connor,David P Kao, ","doi":"10.1016/j.jchf.2025.102849","DOIUrl":"https://doi.org/10.1016/j.jchf.2025.102849","url":null,"abstract":"BACKGROUNDNoninvasive remote patient monitoring (RPM) captures and transmits physiological (eg, weight) and symptom data to the patient's care team for monitoring outside of the clinic, creating opportunities for early intervention (eg, medical therapy optimization) to avoid decompensation events. Mixed results in studies of noninvasive RPM may stem from the complex design of heart failure programs. In current RPM study reports, many workflow components including data review and clinical responses are reported ambiguously or not at all. Opaque workflows prevent robust evaluation, replication in other studies, and community implementation of heart failure RPM programs.OBJECTIVESThe purpose of this study was to create a set of recommendations and a template for reporting workflow design in the publication of noninvasive RPM studies.METHODSThe Heart Failure Collaboratory, Canadian Heart Failure Society, and members of the European Society of Cardiology formed a multidisciplinary working group. Through an extensive consensus-building process, the authors reviewed existing workflows and data reporting practices and developed \"the 6 Rs\" of RPM Reporting.RESULTSThe authors created a set of recommendations and a template for reporting workflows that is organized around 6 Rs: patient Representativeness, ambulatory data Recording, data Relay to clinicians, clinician data Review, Response, and Recommendations from patients and providers.CONCLUSIONSSystematic use of the 6 Rs of RPM Reporting template will improve the completeness and transparency of workflow reporting of RPM studies. The authors encourage investigators to use this framework and accompanying template during noninvasive RPM trial planning and include completed templates in study publications or as supplemental materials.","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"22 1","pages":"102849"},"PeriodicalIF":13.0,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146021678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implications of Potential Undiagnosed HFpEF on Symptomatic Response With Coronary Revascularization. 潜在未确诊的HFpEF对冠状动脉血运重建术症状反应的影响。
IF 13 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-12 DOI: 10.1016/j.jchf.2025.102899
Nicholas P Bergeron,Alexander C Egbe,William R Miranda,Rajiv Gulati,Ryan T Demmer,Varun Sundaram,Barry A Borlaug,Yogesh N V Reddy
BACKGROUNDAlthough patients with heart failure with preserved ejection fraction (HFpEF) have poor quality of life (QOL) and a high coronary artery disease (CAD) burden, there remains limited evidence guiding revascularization in these patients, in part related to complexity in diagnosis.OBJECTIVESThis study aims to determine the prevalence of likely undiagnosed HFpEF in patients with CAD and a positive stress test result, as well as its therapeutic interaction with an invasive strategy on QOL.METHODSPatients without known heart failure (HF) from the ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) trial were stratified by the Rose Dyspnea Scale questionnaire and HFpEF-ABA (heart failure with preserved ejection fraction algorithm using age, body mass index, and history of atrial fibrillation) probability into 3 groups: 1) probable HFpEF (dyspnea and HFpEF-ABA ≥75%); 2) possible HFpEF (dyspnea and HFpEF-ABA <75%); and 3) no HFpEF (no dyspnea). The effect of an invasive strategy on health status was determined using mixed models. The study independently tested the prevalence of HFpEF by using exercise right-sided heart catheterization in a validation cohort of patients with dyspnea, stress testing, and angiography.RESULTSAmong 4,986 participants, 53.4% had dyspnea and were at risk for HFpEF: 9.0% (n = 450) with probable HFpEF and 44.4% (n = 2,213) with possible HFpEF. Patients in the probable HFpEF group had the worst exercise capacity, angina, dyspnea, and QOL, despite having less obstructive CAD (P < 0.0001 for all). An invasive strategy improved Rose Dyspnea Scale, SAQ (Seattle Angina Questionnaire) QOL, and Euro-QoL-5D results consistently across the 3 groups (P = 0.009; P < 0.0001, and P = 0.05, respectively; interaction P > 0.20 for all), with greater benefits on physical limitation and angina in the probable HFpEF group (SAQ Summary, SAQ Physical Limitation, and SAQ Angina Frequency score interaction P = 0.01; P = 0.01, and P = 0.08, respectively). The probable HFpEF group demonstrated an increased risk of HF hospitalization (HR: 7.2 [95% CI: 3.7-13.8]; P < 0.0001) vs no HFpEF (HR: 5.0 [95% CI: 2.7-9.0]; P < 0.0001) vs possible HFpEF), but an invasive strategy did not mitigate this risk (HR: 1.5 [95% CI: 0.7-3.5]; P = 0.34). In the validation cohort (n = 237), of those patients with positive stress test results and dyspnea, 85% had HFpEF, and 68% of these patients had elevated left-sided heart filling pressures even at rest.CONCLUSIONSMore than one-half of patients with CAD and ischemia have dyspnea, with a high risk of undiagnosed HFpEF in one-tenth of these patients. In this study, patients with a high HFpEF probability had the greatest risk for HF hospitalization, the poorest exercise tolerance, and the most severe symptoms, and they derived the greatest benefit from an invasive strategy for physical limitation and angina. However, despite these improvements, residual dyspnea, QOL impa
背景:尽管保留射血分数(HFpEF)的心力衰竭患者生活质量(QOL)较差,冠状动脉疾病(CAD)负担高,但指导这些患者血运重建术的证据仍然有限,部分原因与诊断的复杂性有关。目的:本研究旨在确定CAD患者中可能未确诊的HFpEF的患病率和应激测试阳性结果,以及其与有创策略对生活质量的治疗相互作用。方法通过Rose呼吸困难量表问卷和HFpEF- aba(基于年龄、体重指数和房颤史的保留射血分数算法)概率对缺血试验中无已知心力衰竭(HF)患者进行分层,分为3组:1)可能的HFpEF(呼吸困难和HFpEF- aba≥75%);2)可能的HFpEF(呼吸困难和HFpEF- aba均为0.20),可能的HFpEF组对身体限制和心绞痛有更大的益处(SAQ Summary, SAQ physical limitation和SAQ angina Frequency评分交互作用P = 0.01, P = 0.01, P = 0.08)。可能HFpEF组与无HFpEF组相比(HR: 5.0 [95% CI: 2.7-9.0]; P < 0.0001), HF住院的风险增加(HR: 7.2 [95% CI: 3.7-13.8]; P < 0.0001),但侵入性策略并没有降低这种风险(HR: 1.5 [95% CI: 0.7-3.5]; P = 0.34)。在验证队列(n = 237)中,在应激试验结果阳性且呼吸困难的患者中,85%患有HFpEF,其中68%的患者即使在休息时左侧心脏充盈压力升高。结论:超过一半的冠心病和缺血患者存在呼吸困难,其中十分之一的患者存在未确诊的HFpEF高风险。在本研究中,HFpEF概率高的患者HF住院风险最大,运动耐受性最差,症状最严重,并且他们从身体限制和心绞痛的侵入性策略中获益最大。然而,尽管有这些改善,血运重建术后,残余呼吸困难、生活质量受损和HF住院风险升高仍然存在。这些数据提示了独立评估冠心病合并呼吸困难患者并发HFpEF的潜在作用。
{"title":"Implications of Potential Undiagnosed HFpEF on Symptomatic Response With Coronary Revascularization.","authors":"Nicholas P Bergeron,Alexander C Egbe,William R Miranda,Rajiv Gulati,Ryan T Demmer,Varun Sundaram,Barry A Borlaug,Yogesh N V Reddy","doi":"10.1016/j.jchf.2025.102899","DOIUrl":"https://doi.org/10.1016/j.jchf.2025.102899","url":null,"abstract":"BACKGROUNDAlthough patients with heart failure with preserved ejection fraction (HFpEF) have poor quality of life (QOL) and a high coronary artery disease (CAD) burden, there remains limited evidence guiding revascularization in these patients, in part related to complexity in diagnosis.OBJECTIVESThis study aims to determine the prevalence of likely undiagnosed HFpEF in patients with CAD and a positive stress test result, as well as its therapeutic interaction with an invasive strategy on QOL.METHODSPatients without known heart failure (HF) from the ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) trial were stratified by the Rose Dyspnea Scale questionnaire and HFpEF-ABA (heart failure with preserved ejection fraction algorithm using age, body mass index, and history of atrial fibrillation) probability into 3 groups: 1) probable HFpEF (dyspnea and HFpEF-ABA ≥75%); 2) possible HFpEF (dyspnea and HFpEF-ABA &lt;75%); and 3) no HFpEF (no dyspnea). The effect of an invasive strategy on health status was determined using mixed models. The study independently tested the prevalence of HFpEF by using exercise right-sided heart catheterization in a validation cohort of patients with dyspnea, stress testing, and angiography.RESULTSAmong 4,986 participants, 53.4% had dyspnea and were at risk for HFpEF: 9.0% (n = 450) with probable HFpEF and 44.4% (n = 2,213) with possible HFpEF. Patients in the probable HFpEF group had the worst exercise capacity, angina, dyspnea, and QOL, despite having less obstructive CAD (P &lt; 0.0001 for all). An invasive strategy improved Rose Dyspnea Scale, SAQ (Seattle Angina Questionnaire) QOL, and Euro-QoL-5D results consistently across the 3 groups (P = 0.009; P &lt; 0.0001, and P = 0.05, respectively; interaction P &gt; 0.20 for all), with greater benefits on physical limitation and angina in the probable HFpEF group (SAQ Summary, SAQ Physical Limitation, and SAQ Angina Frequency score interaction P = 0.01; P = 0.01, and P = 0.08, respectively). The probable HFpEF group demonstrated an increased risk of HF hospitalization (HR: 7.2 [95% CI: 3.7-13.8]; P &lt; 0.0001) vs no HFpEF (HR: 5.0 [95% CI: 2.7-9.0]; P &lt; 0.0001) vs possible HFpEF), but an invasive strategy did not mitigate this risk (HR: 1.5 [95% CI: 0.7-3.5]; P = 0.34). In the validation cohort (n = 237), of those patients with positive stress test results and dyspnea, 85% had HFpEF, and 68% of these patients had elevated left-sided heart filling pressures even at rest.CONCLUSIONSMore than one-half of patients with CAD and ischemia have dyspnea, with a high risk of undiagnosed HFpEF in one-tenth of these patients. In this study, patients with a high HFpEF probability had the greatest risk for HF hospitalization, the poorest exercise tolerance, and the most severe symptoms, and they derived the greatest benefit from an invasive strategy for physical limitation and angina. However, despite these improvements, residual dyspnea, QOL impa","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"3 1","pages":"102899"},"PeriodicalIF":13.0,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145955482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early Diagnosis of ATTR-CM Using Carpal Tunnel Biopsy Examination: EDUCATE: A United Kingdom Prospective Multicenter Study. 利用腕管活检检查早期诊断atr - cm: EDUCATE:一项英国前瞻性多中心研究。
IF 13 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-12 DOI: 10.1016/j.jchf.2025.102890
Yousuf Razvi,Janet Gilbertson,Carlos Heras-Palou,Jeremy Bland,Onur Berber,Dominic Furniss,Akira Wiberg,Ryckie G Wade,Grainne Bourke,Maxim D Horwitz,Nicola Botcher,Mariana Mykytow,Zak Vinnicombe,Yueyang Li,Alexandra Wood,Taryn Youngstein,Aldostefano Porcari,Muhammad Rauf,Josephine Mansell,Awais Sheikh,Rishi Patel,Dorota Rowczenio,David Hutt,Mary M Reilly,Helen J Lachmann,Ashutosh D Wechalekar,Lucia Venneri,Carol Whelan,Ana Martinez-Naharro,Marianna Fontana,Julian D Gillmore,Philip N Hawkins,
BACKGROUNDTransthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized but still underdiagnosed cause of heart failure in older people, typically causing substantial and irreversible cardiac damage before diagnosis. Specific therapies have lately become available that slow disease progression, early diagnosis now being a major priority to improving outcomes. Amyloid-associated carpal tunnel syndrome commonly precedes symptomatic cardiomyopathy, but histological examination at surgical decompression is seldom sought. This multicentre prospective study was conducted to determine whether biopsy at carpal tunnel decompression can aid early diagnosis of ATTR-CM.OBJECTIVESThis study sought to determine whether carpal tunnel biopsies obtained at routine surgical decompression can aid early diagnosis of ATTR-CM.METHODSThis prospective, multicenter, cross-sectional United Kingdom study included unselected patients >50 years of age who were undergoing carpal tunnel decompression and who provided biopsies for amyloid histological examination. Exclusion criteria included the inability to consent and an existing diagnosis of amyloidosis. Patients with biopsy-proven amyloid deposition were invited to undergo repurposed bone scintigraphy, echocardiography, and clinical assessments for systemic amyloidosis.RESULTSA total of 555 patients, including 315 women, were studied with a mean ± SD age of 68.7 ± 11.0 years. The majority (60.3%), had bilateral symptoms, and the biopsy procedure proved safe. Amyloid was identified in 216 (39%) cases (51% of male and 30% of female patients), more frequently in tenosynovial than transverse carpal ligament biopsies (82.6% vs 70.2%; P < 0.001). Of 216 biopsy-positive patients, 116 assented to cardiac assessment. This assessment identified myocardial amyloid by using technetium-3,3-diphosphono-1,2-propanodicarboxlyic acid (Tc-DPD) scintigraphy in 32 of 116 (28%) patients: 26 were male, 10 had Perugini grade 2 uptake, and the remainder had grade 1 uptake. Echocardiography and serum biomarkers identified significant ATTR-CM in patients with Perugini grade 2 DPD scans, prompting commencement of disease-modifying therapy. Two further patients received a diagnosis of unsuspected systemic light-chain (AL) amyloidosis, thus enabling timely chemotherapy.CONCLUSIONSTransthyretin amyloid (ATTR) is commonly present in the tenosynovium and transverse carpal ligaments of older people with carpal tunnel syndrome, and more than one quarter of whom have ATTR cardiac amyloid infiltration that is readily identifiable using bone scintigraphy. Biopsies of samples taken at carpal tunnel decompression present a practicable pathway to enable early diagnosis and treatment of ATTR-CM.
转甲状腺素淀粉样心肌病(atr - cm)是一种日益被认识但仍未被诊断出的老年人心力衰竭原因,通常在诊断前会造成严重且不可逆的心脏损伤。最近出现了减缓疾病进展的特定疗法,早期诊断现在是改善结果的主要优先事项。淀粉样蛋白相关性腕管综合征通常先于症状性心肌病,但在手术减压时很少进行组织学检查。本多中心前瞻性研究旨在确定腕管减压活检是否有助于atr - cm的早期诊断。目的:本研究旨在确定常规手术减压时获得的腕管活检是否有助于atr - cm的早期诊断。方法:这项前瞻性、多中心、横断面的英国研究纳入了未选择的年龄在50岁至50岁之间接受腕管减压术的患者,这些患者接受了淀粉样蛋白组织学检查的活检。排除标准包括不能同意和现有的淀粉样变诊断。活检证实淀粉样蛋白沉积的患者被邀请接受重新定位的骨显像、超声心动图和系统性淀粉样变性的临床评估。结果共纳入555例患者,其中女性315例,平均±SD年龄为68.7±11.0岁。大多数患者(60.3%)有双侧症状,活检证明是安全的。在216例(39%)患者(51%的男性和30%的女性患者)中发现淀粉样蛋白,腱滑膜活检比腕横韧带活检更常见(82.6%比70.2%;P < 0.001)。在216例活检阳性患者中,116例同意进行心脏评估。116例患者中有32例(28%)采用锝-3,3-二膦-1,2-丙二羧酸(Tc-DPD)显像鉴定心肌淀粉样蛋白,其中26例为男性,10例为Perugini 2级摄取,其余为1级摄取。超声心动图和血清生物标志物在Perugini 2级DPD扫描患者中发现了显著的atr - cm,促使开始疾病改善治疗。另外两名患者被诊断为未被怀疑的系统性轻链(AL)淀粉样变,因此能够及时化疗。结论:老年腕管综合征患者的肌腱滑膜和腕横韧带中普遍存在超纤桥蛋白淀粉样蛋白(ATTR),超过1 / 4的患者存在超纤桥蛋白淀粉样蛋白浸润,可通过骨显像识别。在腕管减压时进行活检,为早期诊断和治疗atr - cm提供了可行的途径。
{"title":"Early Diagnosis of ATTR-CM Using Carpal Tunnel Biopsy Examination: EDUCATE: A United Kingdom Prospective Multicenter Study.","authors":"Yousuf Razvi,Janet Gilbertson,Carlos Heras-Palou,Jeremy Bland,Onur Berber,Dominic Furniss,Akira Wiberg,Ryckie G Wade,Grainne Bourke,Maxim D Horwitz,Nicola Botcher,Mariana Mykytow,Zak Vinnicombe,Yueyang Li,Alexandra Wood,Taryn Youngstein,Aldostefano Porcari,Muhammad Rauf,Josephine Mansell,Awais Sheikh,Rishi Patel,Dorota Rowczenio,David Hutt,Mary M Reilly,Helen J Lachmann,Ashutosh D Wechalekar,Lucia Venneri,Carol Whelan,Ana Martinez-Naharro,Marianna Fontana,Julian D Gillmore,Philip N Hawkins, ","doi":"10.1016/j.jchf.2025.102890","DOIUrl":"https://doi.org/10.1016/j.jchf.2025.102890","url":null,"abstract":"BACKGROUNDTransthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized but still underdiagnosed cause of heart failure in older people, typically causing substantial and irreversible cardiac damage before diagnosis. Specific therapies have lately become available that slow disease progression, early diagnosis now being a major priority to improving outcomes. Amyloid-associated carpal tunnel syndrome commonly precedes symptomatic cardiomyopathy, but histological examination at surgical decompression is seldom sought. This multicentre prospective study was conducted to determine whether biopsy at carpal tunnel decompression can aid early diagnosis of ATTR-CM.OBJECTIVESThis study sought to determine whether carpal tunnel biopsies obtained at routine surgical decompression can aid early diagnosis of ATTR-CM.METHODSThis prospective, multicenter, cross-sectional United Kingdom study included unselected patients >50 years of age who were undergoing carpal tunnel decompression and who provided biopsies for amyloid histological examination. Exclusion criteria included the inability to consent and an existing diagnosis of amyloidosis. Patients with biopsy-proven amyloid deposition were invited to undergo repurposed bone scintigraphy, echocardiography, and clinical assessments for systemic amyloidosis.RESULTSA total of 555 patients, including 315 women, were studied with a mean ± SD age of 68.7 ± 11.0 years. The majority (60.3%), had bilateral symptoms, and the biopsy procedure proved safe. Amyloid was identified in 216 (39%) cases (51% of male and 30% of female patients), more frequently in tenosynovial than transverse carpal ligament biopsies (82.6% vs 70.2%; P < 0.001). Of 216 biopsy-positive patients, 116 assented to cardiac assessment. This assessment identified myocardial amyloid by using technetium-3,3-diphosphono-1,2-propanodicarboxlyic acid (Tc-DPD) scintigraphy in 32 of 116 (28%) patients: 26 were male, 10 had Perugini grade 2 uptake, and the remainder had grade 1 uptake. Echocardiography and serum biomarkers identified significant ATTR-CM in patients with Perugini grade 2 DPD scans, prompting commencement of disease-modifying therapy. Two further patients received a diagnosis of unsuspected systemic light-chain (AL) amyloidosis, thus enabling timely chemotherapy.CONCLUSIONSTransthyretin amyloid (ATTR) is commonly present in the tenosynovium and transverse carpal ligaments of older people with carpal tunnel syndrome, and more than one quarter of whom have ATTR cardiac amyloid infiltration that is readily identifiable using bone scintigraphy. Biopsies of samples taken at carpal tunnel decompression present a practicable pathway to enable early diagnosis and treatment of ATTR-CM.","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"9 1","pages":"102890"},"PeriodicalIF":13.0,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145955933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JACC. Heart failure
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1